Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
DALLAS and FORT WORTH, Texas, Aug. 02, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report its second quarter 2017 financial results prior to the opening of U.S. financial markets on Tuesday, August 8, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 51584953. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, and Cotempla XR-ODTTM, indicated for the treatment of ADHD in patients 6 to 17 years old, are the first approved products using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for one other branded product candidate that is an XR medication in oral suspension dosage form. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
